Nicod, Elena http://orcid.org/0000-0001-6798-9923
Lloyd, Andrew J http://orcid.org/0000-0002-7597-6556
Morel, Thomas http://orcid.org/0000-0002-0690-5359
Meregaglia, Michela
Upadhyaya, Sheela
Whittal, Amanda
Facey, Karen http://orcid.org/0000-0001-6670-5271
Drummond, Michael http://orcid.org/0000-0002-6126-0944
Funding for this research was provided by:
Horizon 2020 Framework Programme (779312, 779312, 779312, 779312, 779312, 779312)
Article History
Accepted: 28 August 2022
First Online: 10 October 2022
Declarations
:
: All authors made substantial contributions to the design of the work. EN drafted the work; all authors revised it critically at several occasions for important intellectual content; all authors approved the version being submitted. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
: This research was partially funded by the European Commission’s Horizon 2020 research and innovation programme and was undertaken under the auspices of IMPACT-HTA (Grant number 779312). The results presented here reflect the authors’ views and not the views of the European Commission. The European Commission is not liable for any use of the information communicated.
: Not applicable.
: Not applicable.
: Not applicable.
: All data generated or analysed during this study are referenced in this published article.
: Not applicable.
: Outside of this research: Elena Nicod and Amanda Whittal are also employed by Dolon Ltd. Andrew Lloyd is an employee and shareholder in Acaster Lloyd Consulting Ltd, which receives fees from the pharmaceutical industry to undertake research projects. Michael Drummond has received fees from several pharmaceutical companies to provide advice on HTA. Karen Facey has received fees from several pharmaceutical companies to provide advice on HTA and patient involvement, and from public bodies to provide facilitation. Thomas Morel is an employee and shareholder of UCB Pharma. Sheela Upadhyaya and Michela Meregaglia do not have any competing interests.